🔎 Trials Near Me

Utama › Adenokarsinoma Esofagus › South Dakota

Kajian klinikal Adenokarsinoma Esofagus di South Dakota

5 kajian untuk Adenokarsinoma Esofagus sedang mencari peserta di lokasi di South Dakota.

Bandar di South Dakota

Teks kajian rasmi (Bahasa Inggeris)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Rapid City Regional Hospital, Rapid City
  • Sanford Cancer Center Oncology Clinic, Sioux Falls
  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Avera Cancer Institute-Aberdeen, Aberdeen
  • Avera Cancer Institute - Mitchell, Mitchell
  • Avera Cancer Institute at Pierre, Pierre
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05677490

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Avera Cancer Institute, Sioux Falls
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06324357

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Sioux Falls
  • Research Site, Yankton
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07431281

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Sanford Cancer Center, Sioux Falls
  • Sanford USD Medical Center, Sioux Falls
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT04389632

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.